CA2402602A1 - Polynucleotides de type b2/d+ a- et isoles d'e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides - Google Patents

Polynucleotides de type b2/d+ a- et isoles d'e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides Download PDF

Info

Publication number
CA2402602A1
CA2402602A1 CA002402602A CA2402602A CA2402602A1 CA 2402602 A1 CA2402602 A1 CA 2402602A1 CA 002402602 A CA002402602 A CA 002402602A CA 2402602 A CA2402602 A CA 2402602A CA 2402602 A1 CA2402602 A1 CA 2402602A1
Authority
CA
Canada
Prior art keywords
polynucleotides
coli
group
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002402602A
Other languages
English (en)
Inventor
Edouard Bingen
Stephane Bonacorsi
Olivier Clermont
Xavier Nassif
Colin Tinsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0003145A external-priority patent/FR2806096A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2402602A1 publication Critical patent/CA2402602A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des produits de type B2+ A-, isolés d'E. coli, et leurs applications biologiques, notamment leurs applications médicales (thérapeutiques, vaccinales et diagnostiques) et biotechnologiques. Dans la présente invention l'expression <=de type B2+ A->= est utilisée pour signifier la présence à une fréquence supérieure à 10 % parmi les souches de E. coli de groupe B2 de la collection ECOR, et à une fréquence inférieure à 10 % parmi les souches de groupe A de la même collection. L'invention concerne également un procédé phylogénique permettant notamment de distinguer rapidement et aisément les groupes A, B1, B2 et D des espèces d'E. coli avec une précision supérieure à 99 %.
CA002402602A 2000-03-10 2001-03-12 Polynucleotides de type b2/d+ a- et isoles d'e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides Abandoned CA2402602A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR00/03145 2000-03-10
FR0003145A FR2806096A1 (fr) 2000-03-10 2000-03-10 Produits a propriete b2+ a-isoles a partir de e.coli, et leurs applications biologiques
FR01/01449 2001-02-02
FR0101449 2001-02-02
PCT/EP2001/003445 WO2001066572A2 (fr) 2000-03-10 2001-03-12 Polynucleotides de type b2/d+ a- et isoles d'e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides

Publications (1)

Publication Number Publication Date
CA2402602A1 true CA2402602A1 (fr) 2001-09-13

Family

ID=26212251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002402602A Abandoned CA2402602A1 (fr) 2000-03-10 2001-03-12 Polynucleotides de type b2/d+ a- et isoles d'e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides

Country Status (4)

Country Link
EP (1) EP1328641A2 (fr)
JP (1) JP2004512817A (fr)
CA (1) CA2402602A1 (fr)
WO (1) WO2001066572A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1342784A1 (fr) * 2002-03-06 2003-09-10 Mutabilis S.A. Protéines spécifiques d'ExPEC, gènes correspondants et leur utilisations
EP1858919B1 (fr) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogenes d'escherichia coli uropathogene
EP1858920B1 (fr) * 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteines et acides nucleiques provenant de escherichia coli associe a la meningite/septicemie
JP2010503380A (ja) * 2006-05-10 2010-02-04 アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミック 細胞の増殖を阻害するための細胞変性物質としての特異的ｄｎａ分子を含む細胞の使用法
EP2586790A3 (fr) 2006-08-16 2013-08-14 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
EP2298798B1 (fr) * 2009-09-10 2012-05-09 Freie Universität Berlin L'identification et la caractérisation de la pathogène aviaire adhésine fimbriée (APEC) d'E. coli
WO2013014261A1 (fr) 2011-07-28 2013-01-31 Universiteit Gent Prévention de la recrudescence de salmonella
GB2554742A (en) * 2016-10-07 2018-04-11 Bhongir Ravi Treatment
TW202304504A (zh) * 2021-04-01 2023-02-01 美商詹森藥物公司 大腸桿菌ｏ１８生物軛合物之生產

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078716A1 (fr) * 1992-09-21 1994-03-22 Joyce De Azavedo Proteine de e. coli enterohemorragique de fixation et de destruction
ES2076895B1 (es) * 1994-02-04 1996-08-16 Ind Farma Especial Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.
CA2218601A1 (fr) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Traitement contre escherichia coli producteur de verotoxines
WO1998022575A2 (fr) * 1996-11-22 1998-05-28 Human Genome Sciences, Inc. SEQUENCE NUCLEOTIDIQUE D'ILOTS PATHOGENES D'$i(ESCHERICHIA COLI)

Also Published As

Publication number Publication date
WO2001066572A9 (fr) 2002-08-15
WO2001066572A3 (fr) 2003-05-01
EP1328641A2 (fr) 2003-07-23
WO2001066572A2 (fr) 2001-09-13
JP2004512817A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
Swenson et al. Two pathogenicity islands in uropathogenic Escherichia coli J96: cosmid cloning and sample sequencing
Brunder et al. Novel type of fimbriae encoded by the large plasmid of sorbitol-fermenting enterohemorrhagic Escherichia coli O157: H−
Sohel et al. Enteropathogenic Escherichia coli: identification of a gene cluster coding for bundle-forming pilus morphogenesis
Pupo et al. Evolutionary relationships among pathogenic and nonpathogenic Escherichia coli strains inferred from multilocus enzyme electrophoresis and mdh sequence studies
Karch et al. Clonal structure and pathogenicity of Shiga-like toxin-producing, sorbitol-fermenting Escherichia coli O157: H
Kao et al. Pathogenicity island sequences of pyelonephritogenic Escherichia coli CFT073 are associated with virulent uropathogenic strains
Nishibuchi et al. Cloning and nucleotide sequence of the gene (trh) encoding the hemolysin related to the thermostable direct hemolysin of Vibrio parahaemolyticus
Darfeuille-Michaud et al. R-plasmid-encoded adhesive factor in Klebsiella pneumoniae strains responsible for human nosocomial infections
Occhino et al. Vibrio cholerae iron transport: haem transport genes are linked to one of two sets of tonB, exbB, exbD genes
Zhu et al. The opcA and ΨopcB regions in Neisseria: genes, pseudogenes, deletions, insertion elements and DNA islands
Reidl et al. Lipoprotein e (P4) is essential for hemin uptake by Haemophilus influenzae.
US20080241151A1 (en) Virulence genes, proteins, and their use
Karunakaran et al. Isolation and characterization of a hemin-regulated gene, hemR, from Porphyromonas gingivalis
CA2402602A1 (fr) Polynucleotides de type b2/d+ a- et isoles d&#39;e.coli, et applications biologiques de tels polynucleotides et leurs polypeptides
Wiggerich et al. Unusual structure of the tonB-exb DNA region of Xanthomonas campestris pv. campestris: tonB, exbB, and exbD1 are essential for ferric iron uptake, but exbD2 is not
US20090298713A1 (en) Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides
Li et al. Detection and characterization of thefimAgene ofEscherichia coliO157: H7
Harrington et al. Epidemiology of Salmonella sofia in Australia
US6156546A (en) Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
Yan et al. DNA sequence and analysis of a 90.1-kb plasmid in Shiga toxin-producing Escherichia coli (STEC) O145: NM 83-75
Merino et al. A C1q-binding 40 kDa porin from Aeromonas salmonicida: cloning, sequencing, role in serum susceptibility and fish immunoprotection
Stojiljkovic et al. Identification of the hopG gene, a component of Escherichia coli K-12 type II export system, and its conservation among different pathogenic Escherichia coli and Shigella isolates
Nagano et al. Clonal structure of Shiga toxin (Stx)-producing and β-D-glucuronidase-positive Escherichia coli O157: H7 strains isolated from outbreaks and sporadic cases in Hokkaido, Japan
Brzostek et al. The YompC protein of Yersinia enterocolitica: molecular and physiological characterization
Weir et al. Identification of four complete type 4 pilin genes in a single Kingella denitrificans genome

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130312